OR
Live price temporarily unavailable.
Price history
Oramed Pharmaceuticals (ORMP) is a Health Care company in the Russell 2000. Latest news and coverage below.
Oramed Pharmaceuticals revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Aug 2016 | FY2017Aug 2017 | FY2018Aug 2018 | FY2019Aug 2019 | FY2020Aug 2020 | FY2021Aug 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $641.0K | $2.46M | $2.45M | $2.70M | $2.71M | $2.70M | $2.70M | $1.34M | — | $2.00M |
| Growth (year over year) | — | +283.2% | −0.3% | +10.4% | +0.3% | −0.3% | 0.0% | −50.4% | — | — |
| Gross profit | $151.0K | $2.27M | — | $2.61M | — | — | — | — | — | $13.0K |
| Gross margin | 23.6% | 92.4% | — | 96.7% | — | — | — | — | — | 0.7% |
| Operating income | −$10.0M | −$10.8M | −$13.5M | −$14.6M | −$11.8M | −$24.2M | −$40.6M | −$15.8M | −$12.8M | −$15.1M |
| Operating margin | −1561.6% | −438.6% | −552.3% | −541.3% | −433.8% | −896.2% | −1502.0% | −1176.8% | — | −754.4% |
| Net income | −$11.0M | −$10.5M | −$12.7M | −$14.4M | −$11.5M | −$23.0M | −$36.6M | $5.09M | −$19.1M | $64.0M |
| Net margin | −1710.5% | −426.7% | −519.7% | −531.1% | −424.8% | −850.5% | −1352.6% | 379.7% | — | 3202.5% |
| EPS (diluted) | $0.87 | $0.79 | $0.86 | $0.82 | $0.56 | $0.78 | −$0.94 | $0.14 | −$0.48 | $1.50 |
| Balance sheet | ||||||||||
| Cash and equivalents | $3.91M | $3.97M | $5.00M | $3.33M | $19.3M | $77.2M | $40.5M | $9.05M | $54.4M | $45.9M |
| Total assets | $42.8M | $38.7M | $47.4M | $34.7M | $44.6M | $128.0M | $161.6M | $220.6M | $155.3M | $230.9M |
| Total liabilities | $16.6M | $19.5M | $16.3M | $15.3M | $11.8M | $11.5M | $10.5M | $57.7M | $9.93M | $31.1M |
| Long-term debt | — | — | $11.4M | $9.66M | — | $12.5M | $25.0K | — | — | — |
| Shareholders' equity | $26.2M | $19.2M | $31.1M | $19.4M | $32.9M | $115.8M | $151.8M | $163.8M | $146.3M | $199.7M |
| Cash flow | ||||||||||
| Operating cash flow | $4.66M | −$5.83M | −$14.7M | −$12.9M | −$12.4M | −$21.2M | −$27.9M | −$10.3M | −$8.41M | −$9.14M |
| Capital expenditure | $9.00K | $7.00K | $5.00K | $15.0K | $82.0K | $375.0K | $496.0K | $254.0K | $18.0K | $9.00K |
| Free cash flow | $4.65M | −$5.84M | −$14.7M | −$13.0M | −$12.5M | −$21.6M | −$28.4M | −$10.5M | −$8.43M | −$9.15M |
| Share buybacks | — | — | — | — | — | — | — | — | $2.48M | $4.74M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $2.00M | $0 | $0 | — | — | — |
| Gross profit | — | — | $13.0K | $0 | $0 | — | — | — |
| Gross margin | — | — | 0.7% | — | — | — | — | — |
| Operating income | −$3.09M | −$3.60M | −$4.50M | −$2.49M | −$2.43M | — | −$3.66M | −$2.77M |
| Operating margin | — | — | −225.0% | — | — | — | — | — |
| Net income | −$19.6M | −$10.2M | −$7.64M | $13.3M | $48.4M | — | $38.3M | $78.2M |
| Net margin | — | — | −382.1% | — | — | — | — | — |
| EPS (diluted) | −$0.48 | −$0.26 | −$0.19 | $0.31 | $1.13 | — | $0.91 | $1.84 |
| Balance sheet | ||||||||
| Cash and equivalents | $42.1M | $54.4M | $74.5M | $15.8M | $52.2M | $45.9M | $13.2M | $15.2M |
| Total assets | $165.1M | $155.3M | $147.5M | $161.7M | $220.5M | $230.9M | $268.8M | $369.6M |
| Total liabilities | $9.56M | $9.93M | $7.64M | $8.10M | $18.2M | — | $30.6M | $52.2M |
| Shareholders' equity | $156.4M | $146.3M | $140.8M | $154.5M | $203.3M | $199.7M | $238.3M | $317.5M |
| Cash flow | ||||||||
| Operating cash flow | −$7.10M | −$1.91M | −$3.52M | −$3.54M | −$1.63M | — | −$2.92M | −$200.0K |
| Capital expenditure | $5.00K | $11.0K | $3.00K | $4.00K | $0 | — | $5.00K | $2.00K |
| Free cash flow | −$7.11M | −$1.92M | −$3.52M | −$3.54M | −$1.63M | — | −$2.92M | −$202.0K |
| Dividends paid | — | — | — | — | — | — | $10.4M | $78.0K |
| Share buybacks | — | $1.19M | — | — | $361.0K | — | — | — |
From Oramed Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Oramed Pharmaceuticals
- Headquarters
- New York, New York From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International